NCT07145229招募中2 期
A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects With an Acute Gout Flare
Atom Therapeutics Co., Ltd35 个研究点 分布在 3 个国家目标入组 380 人开始时间: 2025年8月26日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 380
- 试验地点
- 35
- 主要终点
- Change in Visual Analog Scale (VAS) pain score of the target joint
研究概览
简要总结
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects are eligible for the study if they meet all of the following Inclusion Criteria:
- •Age 18-70 years old (inclusive), male or female.
- •Body mass index (BMI)18-40 kg/m2 (inclusive).
- •Medical history and current findings consistent with diagnosis of gouty arthritis.
- •Subjects must have experienced 2 or more gout flares within 12 months prior to screening.
- •Onset of an acute gout flare, within 6 months
- •Patients receiving ULT agents (such as allopurinol, febuxostat, probenecid, etc.) must be on stable doses of these drugs prior to first dose of study drug (and remain on the same dose throughout the Treatment Period).
- •Subjects agree to maintain a stable lifestyle (such as diet and exercise) during the study period.
排除标准
- •Subjects are excluded from the study if one or more of the following criteria are met:
- •Administration of oral prednisone ≥ 10 mg or equivalent doses of other glucocorticoids, or use of narcotics, within 24 hours prior to first dose of study drug, or intramuscular, intravenous, or intra-articular injection of any glucocorticoid within 14 days prior to first dose of study drug.
- •Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) prior to first dose dose of study drug, at the investigator's discretion.
- •Administration of colchicine or ABP-745 within 14 days prior to first dose of study drug.
- •Subjects took any investigational drug in any clinical study within 1 month prior to first dose of study drug and throughout the study period.
- •Administration of pegloticase, or methotrexate, or any biologic IL-1 blocker, TNF inhibitor, or other biological agent within 30 days prior to first dose of study drug or within 5 half-lives of the study drug prior to the first dose of study drug, whichever is longer.
- •Administration of muscle relaxants, central stimulants, barbiturates, etc. within 30 days prior to first dose of study drug or within 5 half-lives of the drug prior to the first dose of study drug, whichever is longer.
- •Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout).
- •Subjects with a current diagnosis or history of rheumatoid arthritis, psoriatic arthritis, evidence or suspicion of infectious/septic arthritis, calcium pyrophosphate (CPP) crystal arthritis, acute polyarticular gout (4 or more joints), multiple sclerosis or any other demyelinating disease, or; major chronic inflammatory disease or connective tissue disease other than RA or psoriatic arthritis (PsA), including but not limited to fibromyalgia or systemic lupus erythematosus (with the exception of secondary Sjögrens syndrome, etc.); with arthritis due to any cause other than gout that may confound any study assessments per Investigator discretion or Prosthetic joint infection within 5 years of screening, or native joint infection within 1 year of screening
- •Current anticoagulation therapy, thrombocytopenia, or diseases with a risk of thrombocytopenia, such as aplastic anemia, hypersplenism, or known hemorrhagic diseases like idiopathic thrombocytopenic purpura or hemophilia.
- •History of malignancy within 5 years prior to screening, excluding localized cancers such as basal cell carcinoma.
- •Presence of significant diseases, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥160 or diastolic blood pressure ≥100 mmHg), congestive heart failure (New York Heart Association [NYHA] class III or above), uncontrolled type 1 or 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8.5%). Inclusion will be determined by the Investigator based on the subject's specific condition.
- •Women of childbearing potential as defined by Appendix
- •Experienced only no or mild gout-related pain prior to first dose of study drug.
- •Use of gout flare prophylaxis (e.g., colchicine, NSAIDs, prednisone/methylprednisolone) at the time of randomization based on conversation with subject and self-reported.
- •Corona Virus Disease (COVID) vaccination in the 4 weeks prior to randomization.
研究组 & 干预措施
ABP-745 Dose A
Experimental
干预措施: ABP-745 Dose A (Drug)
ABP-745 Dose B
Experimental
干预措施: ABP-745 Dose B (Drug)
Colchicine
Active Comparator
干预措施: Colchicine (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Visual Analog Scale (VAS) pain score of the target joint
时间窗: 24 hours post the first dose of study drug
Change from baseline in 0-100 mm VAS pain score of the target joint
次要结局
- Change and percentage change from baseline in VAS pain score of the target joint(2-8 days post the first dose of study drug)
- Incidence of treatment-emergent adverse events (Safety and Tolerability)(up to 14 days post the first dose of study drug)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
2 期
Study To Assess FRacTure Healing With SclerosTin Antibody - HipFracture HealingNCT01081678Amgen332
已完成
3 期
Evaluate the Neurological Effects of EryDex on Subjects With A-TAtaxia TelangiectasiaNCT06193200Quince Therapeutics S.p.A.105
招募中
3 期
Treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S aureus) in combination with standard of care (SOC) antibiotic therapyCTRI/2020/05/025104Aridis Pharmaceuticals Inc240
终止
3 期
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial HypertensionPulmonary HypertensionNCT00302211Actelion67
已完成
3 期
To study the effect and safety of drug product Romosozumab in Postmenopausal Women With Osteoporosis.CTRI/2012/10/003078Amgen Technology Pvt Ltd6,600